EUVIMEDEUVIMED entdecken
Crossref

Self‐Assembled Multiepitope Nanovaccine Provides Long‐Lasting Cross‐Protection against Influenza Virus

Jiaojiao Nie iD, Qingyu Wang, Chenxi Li, Yongfei Zhou, Xin Yao, Lipeng Xu, Yaotian Chang, Fan Ding, Lulu Sun, Li Zhan, Lvzhou Zhu, Kunpeng Xie und 4 weitere

Advanced Healthcare Materials · 2024

DOI: 10.1002/adhm.202303531 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2024. Verfasst von Jiaojiao Nie und 15 weiteren Autor:innen. Beteiligte Einrichtung: National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, 2699 Qianjin Street, Changchun, 130012, China. Hauptthemen laut MEDLINE: Influenza A Virus, H1N1 Subtype, Influenza, Human, Influenza Vaccines, Orthomyxoviridae Infections. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Changchun Science and Technology Planning Project, Jilin Scientific and Technological Development Program, Graduate Innovation Fund of Jilin University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Seasonal influenza vaccines typically provide strain‐specific protection and are reformulated annually, which is a complex and time‐consuming process. Multiepitope vaccines, combining multiple conserved antigenic epitopes from a pathogen, can trigger more robust, diverse, and effective immune responses, providing a potential solution. However, their practical application is hindered by low immunogenicity and short‐term effectiveness. In this study, multiple linear epitopes from the conserved stem domain of hemagglutinin and the ectodomain of matrix protein 2 are combined with the Helicobacter pylori ferritin, a stable self‐assembled nanoplatform, to develop an influenza multiepitope nanovaccine, named MHF. MHF is prokaryotically expressed in a soluble form and self‐assembles into uniform nanoparticles. The subcutaneous immunization of mice with adjuvanted MHF induces cross‐reactive neutralizing antibodies, antibody‐dependent cell‐mediated cytotoxicity, and cellular immunity, offering complete protection against H3N2 as well as partial protection against H1N1. Importantly, the vaccine cargo delivered by ferritin triggers epitope‐specific memory B‐cell responses, with antibody level persisting for over 6 months post‐immunization. These findings indicate that self‐assembled multiepitope nanovaccines elicit potent and long‐lasting immune responses while significantly reducing the risk of vaccine escape mutants, and offer greater practicality in terms of scalable manufacturing and genetic manipulability, presenting a promising and effective strategy for future vaccine development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza A Virus, H1N1 SubtypeInfluenza, HumanInfluenza VaccinesOrthomyxoviridae InfectionsAnimalsMiceHumansNanovaccinesInfluenza A Virus, H3N2 SubtypeAntibodies, ViralEpitopesFerritinsMice, Inbred BALB C

Stichwörter der Autor:innen

hemagglutinin stem domaininfluenza A viruslong‐lasting cross‐protectionmatrix protein 2 ectodomainmultiepitope nanovaccineself‐assembled ferritin

Substanzen

NanovaccinesAntibodies, ViralInfluenza VaccinesEpitopesFerritins

Autor:innen und Institutionen

  • National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, 2699 Qianjin Street, Changchun, 130012, China.
  • Cancer Centre, Faculty of Health Sciences, University of Macau, Taipa, Macau, 519000, China.
  • MoE Frontiers Science Center for Precision Oncology, University of Macau, Taipa, Macau SAR, 519000, China.
  • Key Laboratory for Molecular Enzymology and Engineering, The Ministry of Education, School of Life Sciences, Jilin University, 2699 Qianjin Street, Changchun, 130012, China.

ORCID-Profile: Jiaojiao Nie, Yaming Shan

Förderung

  • Changchun Science and Technology Planning Project
  • Jilin Scientific and Technological Development Program
  • Graduate Innovation Fund of Jilin University

Zitieren

APA

Nie, J., Wang, Q., Li, C., Zhou, Y., Yao, X., Xu, L., Chang, Y., Ding, F., Sun, L., Zhan, L., Zhu, L., Xie, K., Wang, X., Shi, Y., Zhao, Q., & Shan, Y. (2024). Self‐Assembled Multiepitope Nanovaccine Provides Long‐Lasting Cross‐Protection against Influenza Virus. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202303531

Vancouver

Nie J, Wang Q, Li C, Zhou Y, Yao X, Xu L, et al. Self‐Assembled Multiepitope Nanovaccine Provides Long‐Lasting Cross‐Protection against Influenza Virus. Advanced Healthcare Materials. 2024. doi:10.1002/adhm.202303531

BibTeX
@article{Nie2024,
  author = {Nie, Jiaojiao and Wang, Qingyu and Li, Chenxi and Zhou, Yongfei and Yao, Xin and Xu, Lipeng and Chang, Yaotian and Ding, Fan and Sun, Lulu and Zhan, Li and Zhu, Lvzhou and Xie, Kunpeng and Wang, Xu and Shi, Yuhua and Zhao, Qi and Shan, Yaming},
  title = {Self‐Assembled Multiepitope Nanovaccine Provides Long‐Lasting Cross‐Protection against Influenza Virus},
  journal = {Advanced Healthcare Materials},
  year = {2024},
  doi = {10.1002/adhm.202303531}
}
Kostenlos starten →